

RESEARCH ARTICLE

# Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients

Jae Won Park<sup>1</sup>, Dong Hoon Koh<sup>2</sup>, Won Sik Jang<sup>2</sup>, Joo Yong Lee<sup>2</sup>, Kang Su Cho<sup>2</sup>, Won Sik Ham<sup>2</sup>, Koon Ho Rha<sup>2</sup>, Woo Hee Jung<sup>3</sup>, Sung Joon Hong<sup>2</sup>, Young Deuk Choi<sup>2\*</sup>

**1** Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang, Korea, **2** Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea, **3** Department of Pathology, Yonsei University College of Medicine, Seoul, Korea

\* [youngd74@yuhs.ac](mailto:youngd74@yuhs.ac)



**OPEN ACCESS**

**Citation:** Park JW, Koh DH, Jang WS, Lee JY, Cho KS, Ham WS, et al. (2018) Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients. *PLoS ONE* 13(6): e0199365. <https://doi.org/10.1371/journal.pone.0199365>

**Editor:** Aamir Ahmad, University of South Alabama Mitchell Cancer Institute, UNITED STATES

**Received:** January 19, 2018

**Accepted:** June 6, 2018

**Published:** June 20, 2018

**Copyright:** © 2018 Park et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** Data are restricted due to patients' privacy and research ethics by the Severance Hospital and Urological Science Institution, Yonsei University College of Medicine Data Access and Ethics Committee. The release of patient data to the public would be a violation of IRB terms of approval. Qualifying researchers may apply for data access with Yonsei University College Institutional Review Board at [irb@yuhs.ac](mailto:irb@yuhs.ac).

**Funding:** The authors received no specific funding for this work.

## Abstract

### Purpose

Prostate cancer (PC) is a devastating and heterogeneous condition with diverse treatment options. When selecting treatments for patients with very high-risk PC, clinicians must consider patient comorbidities. We investigated the efficacy of the age-adjusted Charlson Comorbidity Index (ACCI) as a prognostic factor for patient outcomes after radical prostatectomy (RP).

### Materials and methods

We retrospectively investigated the medical records of PC patients at our institution who underwent RP from 1992 to 2010. Very high-risk PC was defined according to National Comprehensive Cancer Network guidelines. Patients with incomplete medical records or who had received neoadjuvant therapy were excluded. Preoperative comorbidity was evaluated by the ACCI, and the prognostic efficacy of the ACCI was analyzed using univariable and multivariable Cox regression, competing risk regression model and Kaplan-Meier curves.

### Results

Our final analysis included 228 men with a median age of 66 years (interquartile range 62–71) and median prostate specific antigen of 10.7 ng/mL. There were 41 (18%) patients with an ACCI score >3 and 88 (38.6%) patients with a biopsy Gleason score >8. Preoperative evaluation revealed that 159 patients (69.7%) had a non-organ confined tumor (≥T3). Following RP, 8-year prostate cancer-specific survival (PCSS) and overall survival (OS) rates were 91.6% and 83.4%, respectively. Competing risk regression analysis revealed that ACCI was significantly associated with other-cause survival and OS ( $p < 0.05$ ).

**Competing interests:** The authors have declared that no competing interests exist.

## Conclusion

The ACCI is an effective prognostic factor for other-cause survival and OS in very high-risk PC patients. RP should be considered carefully for patients with an ACCI score >3.

## Introduction

Prostate cancer (PC) is the most prominent newly-diagnosed cancer and the third highest cause of cancer-related deaths in the United States [1]. Because PC is highly prevalent and devastating, researchers have created a risk classification system based on clinical features of the disease. Previously, D'Amico et al. classified PC according to initial prostate-specific antigen (PSA) levels, clinical T stage, and biopsy Gleason score [2]. However, more recent studies indicate the need for a more stratified risk classification system [3]. National Comprehensive Cancer Network (NCCN) guidelines now separate high-risk PC into high- and very high-risk [4]. Given the heterogeneity of PC, diverse treatment options exist depending on disease severity. Radical prostatectomy (RP) is the one of the most widely accepted PC treatments. Although RP previously had adverse effects on urinary health, including urinary incontinence and sexual dysfunction [5], the introduction of robot-assisted surgical systems reduced the rate of RP-induced urinary complications [6]. More recent studies now describe RP as a feasible treatment for patients with locally advanced PC [7] and suggest that it may even be used to treat high-risk PC with similar therapeutic efficacy as other commonly used cancer treatments such as radiation and hormone combined therapy [8, 9].

When selecting from the diverse treatment options for PC, clinicians must consider the overall physical condition of patients, including their age and comorbidities. Comorbidity, in particular, is an important prognostic factor for patients with cancer [10]. The Charlson Comorbidity Index (CCI) is widely used to evaluate comorbidity in clinical practice [11]. In addition, age was also combined to CCI as an important prognostic factor, according to validation process [12]. In the context of PC, previous studies report an association between the CCI and survival in men with localized PC [13]. Current NCCN guidelines only recommend RP in young, healthy patients without tumor fixation to the pelvic sidewall [4]. However, RP may potentially be used to treat patients with very high-risk PC. In this study, we hypothesized that age adjusted CCI (ACCI) can predict outcomes following surgical treatment for patients with very high-risk PC. We retrospectively analyzed patient outcomes after RP for correlations between the ACCI and different measures of survival. Our results indicate that the ACCI may be used as a prognostic factor for survival after RP in patients with very high-risk PC.

## Materials and methods

Data were collected with approval from the Institutional Review Board at the Yonsei University College of Medicine (No. 4-2017-0864). We retrospectively reviewed the medical records of 4,440 patients who underwent RP at Yonsei University Health System from 1992 to 2010. For all patients analyzed, RP was performed by multiple surgeons using open or robot-assisted laparoscopic techniques. Patients with incomplete medical records or those who had received neoadjuvant therapy were excluded. Patients were classified into clinical risk groups according to NCCN guidelines. Very high-risk PC was defined as PC with clinical T3b or T4, a primary biopsy Gleason pattern of 5, a biopsy Gleason grade 5, and more than four biopsy cores with a Gleason grade of 4 or 5.[4] Tumor, node, and metastasis (TNM) stage was determined according to the American Joint Committee on Cancer 8<sup>th</sup> edition.

Parameters recorded from these very high-risk PC patients included age, body mass index, initial PSA, prostate volume measured by transrectal ultrasonography, number of prostate biopsy cores, percentage of positive cores and pathologic features of the specimen at the time of RP. Additionally, biochemical recurrence (BCR)-free survival, PC-specific survival (PCSS), other-cause survival (OCS) and overall survival (OS) rates were analyzed. BCR was defined as subsequent detectable PSA values that increased at two or more time points.[4] Data regarding mortality and cause of death were obtained from the Yonsei Cancer Registry Center database at Severance Hospital. PC-specific mortality was defined as death after RP caused by PC or PC-related complications, whereas other-cause mortality was defined as deaths resulting from causes other than PC or complications of PC. Overall mortality was defined as death from any cause. Patient comorbidities were assessed by the ACCI, which was calculated from hospital discharge records.[11] The CCI included 19 conditions with scores assigned based on the severity of each disease. Beginning at the age of 50 years, one point was added to the CCI for every subsequent decade. PC was not included for the calculation of the CCI in this study.

Univariable and multivariable Cox regression analyses were performed on clinical parameters to investigate associations between different prognostic factors and OS. Competing risk regression model was also performed for PCSS and OCS with clinical parameters. Kaplan-Meier curves were used to compare PCSS, OCS and OS in two patient groups: high ( $>3$ ) and low ( $\leq 3$ ) ACCI groups. Octogenarian or septuagenarian prostate cancer patients are known to have poor overall survival after RP or radiotherapy, and ACCI scores for these patients total at least 3 by ACCI calculation formula.[14] Meanwhile, an ACCI score  $>3$  has been shown to be associated with mortality risk in other malignancies.[15] In Surveillance, Epidemiology, and End Results (SEER) database, prostate cancer is most frequently diagnosed among men aged 65–74 years, and their ACCI score are 3 if they have no co-morbidity or minor co-morbidity.[16] Thus, we chose an ACCI score of 3 as a cut-off value.

All statistical analysis was performed using SPSS Statistics software, version 23.0 (IBM, Armonk, NY, USA) and R statistical software (version 3.1.0, R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org>), using the `cmprsk` and `riskRegression` packages for competing risk regression.

## Results

A total of 228 patients met the selection criteria and were included in this study. The median follow-up duration was 100 months. Descriptive statistics of patient demographic data and prostate characteristics are displayed in Table 1. The median age was 66 years (interquartile range [IQR] 62–71), and the median prostate volume was 30 mL (IQR 25–40). The median PSA level was 10.7 ng/mL (IQR 7.0–17.4). The median number of positive cores was five (IQR 2–7), and the median percentage of positive biopsy cores was 41.6% (IQR 20.0–66.7). Of these patients, 41 (18%) had an ACCI score  $>3$ . There were 88 (38.6%) patients with a Gleason score  $>8$  at the time of prostate biopsy and 159 (69.7%) patients with clinical, non-organ confined PC ( $\geq T3$ ). After RP, these numbers increased to 120 (52.6%) patients with a Gleason score  $>8$  and 179 (78.5%) patients with pathological, non-organ confined PC. Surgical margins were involved in 142 (62.3%) cases, with lymph node invasion diagnosed in 26 (11.4%) instances. Following RP, the 8-year BCR-free survival rate was relatively low at 44.1%. However, patient survival after RP was high, with 8-year PCSS and OS rates of 91.6% and 83.4%, respectively. There were 23 cases for PC-specific mortality and 23 cases for other-cause mortality during the follow-up period.

Competing risk regression model was also performed for PCSS and OCS as displayed in Table 2. OCS was significantly associated with ACCI (HR 3.66, 95% CI 1.44–9.26). Competing risk regression analysis performed for PCSS revealed associations with a biopsy Gleason score

**Table 1. Baseline characteristics.**

|   | Median | IQR       |
|---|--------|-----------|
| Age, year                               | 66     | 62–71     |
| BMI, kg/m <sup>2</sup>                  | 24.2   | 22.3–26.0 |
| Prostate volume measured by TRUS, mL    | 30     | 25–40     |
| PSA level, ng/mL                        | 10.7   | 7.0–17.4  |
| Number of positive core                 | 5      | 2–7       |
| Percentage of positive core, %          | 41.6   | 20.0–66.7 |
| Tumor volume at specimen, cc            | 3      | 1.5–6.8   |
| Biopsy Gleason score                    | N      | %         |
|   | ≤8     | 140 61.4% |
|   | ≥9     | 88 38.6%  |
| Clinical T stage                        |        |           |
|   | ≤T2    | 69 30.3%  |
|   | ≥T3    | 159 69.7% |
| Pathologic Gleason score                |        |           |
|   | ≤8     | 108 47.4% |
|   | ≥9     | 120 52.6% |
| Pathologic T stage                      |        |           |
|   | ≤T2    | 49 21.5%  |
|   | ≥T3    | 179 78.5% |
| Positive surgical margin                | 142    | 62.3%     |
| Pathologic LN metastasis                | 26     | 11.4%     |
| Age adjusted Charlson Comorbidity Index |        |           |
|   | ≤3     | 187 82%   |
|   | >3     | 41 18%    |
| 8Y BCR free survival rate               |        | 44.1%     |
| 8Y PC specific survival rate            |        | 91.6%     |
| 8Y Overall survival rate                |        | 83.4%     |

BCR = biochemical recurrence; BMI = body mass index; IQR = Interquartile range; LN = Lymph node; PC = prostate cancer; PSA = prostate specific antigen; TRUS = transrectal ultrasonography

<https://doi.org/10.1371/journal.pone.0199365.t001>

≥9 (HR 3.57, 95% CI 1.06–12.73), as reported in Table 3. In univariable competing risk regression analysis, only a single significant variable was observed. Therefore, we performed multivariable competing risk analysis using variables related to cancer characteristics. PSA level and clinical T stage were not associated with PCSS.

Univariable and multivariable Cox regression analyses were performed for OS. OS was significantly correlated with biopsy Gleason Score (HR 1.91, 95% CI 1.05–3.47) and ACCI score >3 (HR 2.71, 95% CI 1.36–5.40). PSA level and clinical T stage did not correlate with OS.

There were no differences in the Kaplan-Meier curves of PCSS between the high (ACCI >3) and low ACCI groups (ACCI ≤3; log rank test, p = 0.09; Fig 1). Kaplan-Meier curves for OCS and OS revealed that for both measures, the high ACCI group had lower OCS (p<0.01; Fig 2) and OS (p<0.01; Fig 3) rates than the low ACCI group. Together, these data suggest that ACCI can be used as a predictor of patient survival after RP.

## Discussion

In this study, we identified a new prognostic factor for predicting survival after RP in patients with PC. PC is a devastating condition that is currently the most prominent type of newly

**Table 2. Competing risk regression analysis for prostate cancer-specific survival and other-cause specific survival.**

|                                       | Prostate cancer-specific survival |                   |                  |         | Other-cause survival |         |                  |         |
|---------------------------------------|-----------------------------------|-------------------|------------------|---------|----------------------|---------|------------------|---------|
|                                       | Univariable                       |                   | Multivariable    |         | Univariable          |         | Multivariable    |         |
|                                       | HR (95% CI)                       | p Value           | HR (95% CI)      | p Value | HR (95% CI)          | p Value | HR (95% CI)      | p Value |
| Age, year                             | 1.06 (0.99–1.12)                  | 0.06              |                  |         | 1.10 (1.03–1.17)     | <0.01   | 1.05 (0.98–1.12) | 0.18    |
| BMI, kg/m <sup>2</sup>                | 0.98 (0.78–1.23)                  | 0.85              |                  |         | 0.96 (0.79–1.17)     | 0.69    |                  |         |
| PSA level, ng/mL                      | 1.00 (0.98–1.01)                  | 0.57              | 0.99 (0.98–1.01) | 0.90    | 0.98 (0.96–1.01)     | 0.15    |                  |         |
| Biopsy Gleason score                  |                                   | <0.01             |                  | 0.04    |                      | 0.69    |                  |         |
|                                       | ≤8                                | 1 (ref)           | 1 (ref)          |         | 1 (ref)              |         |                  |         |
|                                       | ≥9                                | 4.27 (1.64–10.75) | 3.57(1.06–12.73) |         | 0.84 (0.36–1.97)     |         |                  |         |
| Number of positive biopsy core        | 0.95 (0.82–1.11)                  | 0.55              | 1.02 (0.72–1.44) | 0.92    | 0.98 (0.87–1.10)     | 0.67    |                  |         |
| Percentage of positive biopsy core, % | 0.99 (0.97–1.00)                  | 0.15              | 0.99 (0.95–1.03) | 0.48    | 0.99 (0.98–1.01)     | 0.46    |                  |         |
| Clinical T stage                      |                                   | 0.59              |                  | 0.47    |                      | 0.92    |                  |         |
|                                       | ≤T2                               | 1 (ref)           | 1 (ref)          |         | 1(ref)               |         |                  |         |
|                                       | ≥T3                               | 0.80 (0.34–1.82)  | 1.58 (0.45–5.51) |         | 0.96 (0.39–2.32)     |         |                  |         |
| ACCI                                  |                                   | 0.21              |                  |         |                      | <0.01   |                  | <0.01   |
|                                       | ≤3                                | 1(ref)            |                  |         | 1(ref)               |         | 1(ref)           |         |
|                                       | >3                                | 1.79 (0.72–4.47)  |                  |         | 5.02 (0.23–11.30)    |         | 3.66 (1.44–9.26) |         |

<https://doi.org/10.1371/journal.pone.0199365.t002>


diagnosed cancers and the third highest cause of cancer-related deaths in males [1]. Although early stage PC is relatively benign and may not progress under active surveillance [17], advanced PC can become refractory to all known treatments and can be lethal [3]. Thus, research involving PC risk and outcomes is highly relevant. However, PC is a heterogeneous disorder that can be difficult to classify. To contend with this heterogeneity, researchers have developed a risk classification system to identify the risk of PC. Previously, D’Amico et al. suggested that risk classification should be done according to PSA levels, clinical T stage, and biopsy Gleason score [2]. However, patient clinical outcomes varied greatly within a high-risk

**Table 3. Univariable and multivariable Cox regression analysis for overall survival.**

|                                       | Overall survival |                  |                  |         |
|---------------------------------------|------------------|------------------|------------------|---------|
|                                       | Univariable      |                  | Multivariable    |         |
|                                       | HR (95% CI)      | p Value          | HR (95% CI)      | p Value |
| Age, year                             | 1.09 (1.03–1.14) | <0.01            | 1.05 (1.00–1.11) | 0.09    |
| BMI, kg/m <sup>2</sup>                | 0.96 (0.85–1.09) | 0.57             |                  |         |
| PSA level, ng/mL                      | 0.99 (0.97–1.01) | 0.28             |                  |         |
| Biopsy Gleason score                  |                  | 0.03             |                  | 0.03    |
|                                       | ≤8               | 1 (ref)          | 1 (ref)          |         |
|                                       | ≥9               | 1.94 (1.08–3.53) | 1.91 (1.05–3.47) |         |
| Number of positive biopsy core        | 0.96 (0.87–1.06) | 0.44             |                  |         |
| Percentage of positive biopsy core, % | 0.99 (0.98–1.00) | 0.15             |                  |         |
| Clinical T stage                      |                  | 0.65             |                  |         |
|                                       | ≤T2              | 1 (ref)          |                  |         |
|                                       | ≥T3              | 0.87 (0.47–1.61) |                  |         |
| ACCI                                  |                  | <0.01            |                  | <0.01   |
|                                       | ≤3               | 1 (ref)          | 1 (ref)          |         |
|                                       | >3               | 3.52 (1.91–6.51) | 2.71 (1.36–5.40) |         |

BMI = body mass index; ACCI = age adjusted Charlson Comorbidity Index; PSA = prostate specific antigen

<https://doi.org/10.1371/journal.pone.0199365.t003>




**Fig 1. Kaplan-Meier curves of prostate cancer-specific for high ACCI (>3) and low ACCI ( $\leq 3$ ) groups (log rank test;  $p = 0.09$ ).**

<https://doi.org/10.1371/journal.pone.0199365.g001>

PC group when classified by biopsy Gleason score or clinical T stage [18]. Researchers have since suggested that high-risk PC should be further stratified into high- or very high-risk PC [3]. Compared with the standard high-risk PC group, patients with very high-risk PC had significantly worse BCR-free survival, distant metastasis-free survival, and PC-specific mortality [3].

There are many treatment options for PC depending on patient risk classification. For very high-risk PC patients, NCCN guidelines recommend external beam radiotherapy or RP as potential therapies [4]. Fortunately, radical local treatments including surgery or radiotherapy decrease mortality in men with very high-risk PC. Stattin et al. reported that very high-risk PC patients who receive RP or full-dose radiotherapy had lower PC-associated and overall mortality [19]. Thus, RP is a feasible treatment option for very high-risk PC and could result in long-term progression-free survival [9, 19]. Very high-risk PC patients treated with RP also had favorable metastatic progression-free survival, PC-specific mortality-free survival, and OS rates despite receiving a relatively poor prognosis. Surprisingly, their functional outcomes were not any worse than those of standard high-risk PC patients according to Pompe et al [20]. This suggests that RP is an effective treatment option for men with very high-risk PC.

In this study, we sought to identify whether ACCI could serve as a new prognostic factor for the efficacy of RP as a treatment for very high-risk PC, as clinicians consider patient




**Fig 2. Kaplan-Meier curves of other-cause survival for high ACCI (>3) and low ACCI ( $\leq 3$ ) groups (log rank test;  $p < 0.01$ ).**

<https://doi.org/10.1371/journal.pone.0199365.g002>

comorbidities when selecting treatments for patients with PC [21] and typically treat patients with a comorbidity less aggressively than those without a comorbidity [22]. A more accurate risk classification system could improve treatment for older patients without significant comorbidities [23]. Patient comorbidity is also an important independent prognostic factor for cancer outcomes [10]. Indeed, Post et al. reported that comorbidity was the most important prognostic factor for 3-year survival among 1,337 localized-PC patients under the age of 75 years [24]. Although use of the optimal comorbidity index is controversial [25], the CCI is still widely used when selecting treatment options for PC [21, 26, 27].

In a previous study, Lund et al. reported comorbidities in more than one-third of 8,114 newly diagnosed PC patients, with patients with higher CCI scores having higher 1-year mortality rates [28]. Separately, Kastner et al. reported that the CCI was a significant predictor of survival following radical treatment in 37 localized PC patients [26]. After RP, age-adjusted CCI was a significant prognostic factor for long-term survival of patients with high-risk PC. Lee et al. investigated 542 PC patients who underwent RP and reported that ACCI was the most powerful predictor of overall and non-PC-related mortality [29]. In another study, Lee et al. showed that the CCI was associated with OS and non-PCSS in 335 Korean men who underwent RP for PC [30]. However, this study did not identify the optimal selection criteria for surgical treatment of patients with very high-risk PC. Current NCCN guidelines only recommend RP for very high-risk PC patients who are young and healthy [4]. However, optimal





**Fig 3. Kaplan-Meier curves of overall survival for high ACCI (>3) and low ACCI ( $\leq 3$ ) groups (log rank test;  $p < 0.01$ ).**

<https://doi.org/10.1371/journal.pone.0199365.g003>

criteria for the selection of these young and healthy patients are limited. Thus, we attempted to suggest criteria for classification of younger and healthier patients when considering RP. In the current study, we assessed the accuracy of the ACCI as a selection criteria for RP in older patients with very high-risk PC. We compared different survival measures between high CCI (>3) and low CCI ( $\leq 3$ ) groups. As expected, patients with a low ACCI showed significantly more favorable OCS and OS compared with those with a high ACCI. These data support the use of RP for suitable older patients with very high-risk PC.

This study has several limitations. First, analysis was performed retrospectively with a relatively small sample size within a single institution. Thus, a multicenter, prospective study with a larger sample size is needed to generalize this hypothesis. Second, this study included only patients who received RP. Often, healthier patients are selected to undergo surgical treatment rather than a non-surgical treatment such as radiotherapy, which may introduce selection bias. Finally, we only compared patient outcomes between high and low ACCI groups after RP. Future studies should compare very high-risk PC patient outcomes following different treatments or between surgical and non-surgical treatment groups.

Despite these limitations, we show that the ACCI could be a prognostic factor for very high-risk PC patients and should be used when considering surgical treatments for PC. Older or ill patients with an ACCI score  $> 3$  showed significantly worse survival outcomes after RP. This is the first study to identify a threshold ACCI for use when considering RP for



patients with very high-risk PC, which can aid clinicians making treatment decisions for such patients.

## Conclusion

Patient comorbidities should be considered when selecting treatments for PC. The ACCI is a feasible prognostic factor for non-PCSS and OS in very high-risk PC patients. RP should be considered carefully for patients with an ACCI score  $>3$ .

## Author Contributions

**Data curation:** Jae Won Park, Dong Hoon Koh, Won Sik Jang, Joo Yong Lee, Kang Su Cho, Won Sik Ham, Koon Ho Rha, Woo Hee Jung, Sung Joon Hong.

**Formal analysis:** Won Sik Jang.

**Investigation:** Jae Won Park.

**Methodology:** Jae Won Park.

**Project administration:** Jae Won Park, Young Deuk Choi.

**Resources:** Jae Won Park.

**Writing – original draft:** Jae Won Park.

**Writing – review & editing:** Won Sik Jang.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA: a cancer journal for clinicians*. 2017; 67(1):7–30. Epub 2017/01/06. <https://doi.org/10.3322/caac.21387> PMID: 28055103.
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *Jama*. 1998; 280(11):969–74. Epub 1998/09/28. PMID: 9749478.
3. Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, et al. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. *BJU international*. 2017. Epub 2017/05/04. <https://doi.org/10.1111/bju.13903> PMID: 28464446.
4. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN®) clinical practice guidelines in Oncology. Prostate cancer, version 2.2017. Available from: [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf).
5. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2002; 20(2):557–66. Epub 2002/01/12. <https://doi.org/10.1200/jco.2002.20.2.557> PMID: 11786586.
6. Willis DL, Gonzalgo ML, Brotzman M, Feng Z, Trock B, Su LM. Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. *BJU international*. 2012; 109(6):898–905. Epub 2011/09/22. <https://doi.org/10.1111/j.1464-410X.2011.10551.x> PMID: 21933328.
7. Casey JT, Meeks JJ, Greco KA, Wu SD, Nadler RB. Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy. *Journal of endourology*. 2009; 23(9):1519–22. Epub 2009/08/22. <https://doi.org/10.1089/end.2009.0388> PMID: 19694528.
8. Koo KC, Jung DC, Lee SH, Choi YD, Chung BH, Hong SJ, et al. Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged  $\geq 70$  years. *Prostate international*. 2014; 2(3):127–32. Epub 2014/10/18. <https://doi.org/10.12954/PI.14050> PMID: 25325024; PubMed Central PMCID: PMC4186956.
9. Oderda M, Joniau S, Spahn M, Gontero P. Debulking surgery in the setting of very high-risk prostate cancer scenarios. *BJU international*. 2012; 110(6 Pt B):E192–8. Epub 2012/02/09. <https://doi.org/10.1111/j.1464-410X.2012.10942.x> PMID: 22313515.

10. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. *Jama*. 2004; 291(20):2441–7. Epub 2004/05/27. <https://doi.org/10.1001/jama.291.20.2441> PMID: 15161894.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases*. 1987; 40(5):373–83. Epub 1987/01/01. PMID: 3558716.
12. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *Journal of clinical epidemiology*. 1994; 47(11):1245–51. Epub 1994/11/01. PMID: 7722560.
13. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. 2011; 29(10):1335–41. Epub 2011/03/02. <https://doi.org/10.1200/jco.2010.31.2330> PMID: 21357791; PubMed Central PMCID: PMC3084001.
14. Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, et al. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. *Eur Urol*. 2008; 54(1):107–16. Epub 2007/11/13. <https://doi.org/10.1016/j.eururo.2007.10.038> PMID: 17996358.
15. Chang C-M, Yin W-Y, Wei C-K, Wu C-C, Su Y-C, Yu C-H, et al. Adjusted Age-Adjusted Charlson Comorbidity Index Score as a Risk Measure of Perioperative Mortality before Cancer Surgery. *PloS one*. 2016; 11(2):e0148076. <https://doi.org/10.1371/journal.pone.0148076> PMC4744039. PMID: 26848761
16. National Cancer Institute. SEER Cancer Statistics Review, 1975–2014. Available from: [https://seer.cancer.gov/csr/1975\\_2014/](https://seer.cancer.gov/csr/1975_2014/).
17. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. *The Journal of urology*. 2007; 178(3 Pt 2):S14–9. Epub 2007/07/24. <https://doi.org/10.1016/j.juro.2007.03.135> PMID: 17644125; PubMed Central PMCID: PMC3084001.
18. Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? *Urology*. 2010; 76(3):710–4. Epub 2009/11/26. <https://doi.org/10.1016/j.urology.2009.09.014> PMID: 19931898; PubMed Central PMCID: PMC3084001.
19. Stattin P, Sandin F, Thomsen FB, Garmo H, Robinson D, Lissbrant IF, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Seminecologic, Nationwide, Population-based Study. *Eur Urol*. 2017; 72(1):125–34. Epub 2016/08/03. <https://doi.org/10.1016/j.eururo.2016.07.023> PMID: 27481175.
20. Pompe RS, Karakiewicz PI, Tian Z, Mandel P, Steuber T, Schlomm T, et al. Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN(R) Guideline. *The Journal of urology*. 2017. Epub 2017/02/22. <https://doi.org/10.1016/j.juro.2017.02.070> PMID: 28216329.
21. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. *The Journal of urology*. 2011; 185(3):833–9. Epub 2011/01/18. <https://doi.org/10.1016/j.juro.2010.10.061> PMID: 21239002.
22. Jespersen CG, Norgaard M, Jacobsen JB, Borre M. Patient comorbidity is associated with conservative treatment of localized prostate cancer. *Scandinavian journal of urology*. 2015; 49(5):366–70. Epub 2015/04/24. <https://doi.org/10.3109/21681805.2015.1026936> PMID: 25903072.
23. Lunardi P, Ploussard G, Grosclaude P, Roumiguie M, Soulie M, Beauval JB, et al. Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. *World J Urol*. 2017; 35(4):587–93. Epub 2016/07/23. <https://doi.org/10.1007/s00345-016-1900-9> PMID: 27443847.
24. Post PN, Hansen BE, Kil PJ, Janssen-Heijnen ML, Coebergh JW. The independent prognostic value of comorbidity among men aged < 75 years with localized prostate cancer: a population-based study. *BJU international*. 2001; 87(9):821–6. Epub 2001/06/20. PMID: 11412219.
25. Alibhai SM, Leach M, Tomlinson GA, Krahn MD, Fleshner NE, Naglie G. Is there an optimal comorbidity index for prostate cancer? *Cancer*. 2008; 112(5):1043–50. Epub 2008/02/21. <https://doi.org/10.1002/ncr.23269> PMID: 18286512.
26. Kastner C, Armitage J, Kimble A, Rawal J, Carter PG, Venn S. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting. *Prostate cancer and prostatic diseases*. 2006; 9(3):270–4. Epub 2006/06/14. <https://doi.org/10.1038/sj.pcan.4500889> PMID: 16770340.
27. Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Twelker L, Hakenberg OW, et al. Detailed analysis of Charlson comorbidity score as predictor of mortality after radical prostatectomy. *Urology*. 2008; 72(6):1252–7. Epub 2008/08/30. <https://doi.org/10.1016/j.urology.2008.05.037> PMID: 18723211.

28. Lund L, Borre M, Jacobsen J, Sorensen HT, Norgaard M. Impact of comorbidity on survival of Danish prostate cancer patients, 1995–2006: a population-based cohort study. *Urology*. 2008; 72(6):1258–62. Epub 2008/03/18. <https://doi.org/10.1016/j.urology.2007.12.018> PMID: 18342917.
29. Lee JY, Kang HW, Rha KH, Cho NH, Choi YD, Hong SJ, et al. Age-adjusted Charlson comorbidity index is a significant prognostic factor for long-term survival of patients with high-risk prostate cancer after radical prostatectomy: a Bayesian model averaging approach. *Journal of cancer research and clinical oncology*. 2016; 142(4):849–58. Epub 2015/12/15. <https://doi.org/10.1007/s00432-015-2093-0> PMID: 26660495.
30. Lee JY, Lee DH, Cho NH, Rha KH, Choi YD, Hong SJ, et al. Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy. *Yonsei medical journal*. 2014; 55(2):316–23. Epub 2014/02/18. <https://doi.org/10.3349/ymj.2014.55.2.316> PMID: 24532498; PubMed Central PMCID: PMC3936628.